40 results
8-K
EX-99.2
BLUE
Bluebird bio Inc
8 Jan 24
Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024
8:03am
approvals 3 commercial launches Transplant and cell therapy infrastructure Proven reimbursementCl in ic al & p re -c lin ic al c om pa ni es Large cap pharm a Manufacturing experience R&D expertise Commercial infrastructure
8-K
EX-99.1
BLUE
Bluebird bio Inc
7 Nov 23
Results of Operations and Financial Condition
7:01am
partially offset by decreased consulting fees.
R&D Expenses: Research and development expenses were $45.5 million for the three months ended September
8-K
EX-99.1
BLUE
Bluebird bio Inc
8 Aug 23
Regulation FD Disclosure
8:55am
& p re -c lin ic al c om pa ni es Large cap pharm a Manufacturing experience R&D expertise Commercial infrastructure
CONFIDENTIAL bluebird’s five
8-K
EX-99.1
BLUE
Bluebird bio Inc
8 Aug 23
Results of Operations and Financial Condition
7:02am
of potential approval, as well as costs related to employee compensation, benefits, and other head-count related expenses.
R&D Expenses: Research
8-K
EX-99.1
e4x8t77suu
9 May 23
Results of Operations and Financial Condition
7:03am
PRE 14A
v0n94eyc0zj
18 Apr 23
Preliminary proxy
5:09pm
8-K
EX-99.1
gu5mcpzt9gjv u9
7 Nov 22
Results of Operations and Financial Condition
7:02am
8-K
EX-99.1
hrmf3
4 Aug 22
Results of Operations and Financial Condition
4:08pm
8-K
qu0rp 2r2ll7moat
4 Aug 22
Results of Operations and Financial Condition
4:08pm
8-K
EX-99.1
z0m52jiz
9 May 22
Results of Operations and Financial Condition
4:09pm
8-K
EX-99.1
zkttc
4 Mar 22
Results of Operations and Financial Condition
4:32pm
8-K
EX-99.1
u8m5w
5 Nov 21
Results of Operations and Financial Condition
7:08am
8-K
EX-99.1
6t7l 9yn1
8 Sep 21
Business separation of bluebird and 2seventy expected to be completed in October 2021
7:33am
8-K
EX-99.1
gje1x9sp5mw8 jls
9 Aug 21
Results of Operations and Financial Condition
7:02am
8-K
EX-99.1
x39 9iyixu2w4y
28 Jul 21
Bluebird Bio and Resilience Announce Strategic Alliance to Develop Next Generation Cell Therapies
8:04am
8-K
lwcv79gg k3lpr3ji
5 May 21
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
ups6qtqc9btd2erd8c
5 May 21
Results of Operations and Financial Condition
4:10pm